Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 16/20 | 0.65 |
| ▸ | JAK2 | O60674 | 15/20 | 0.65 |
| ▸ | JAK1 | P23458 | 15/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369031 | 0.87 | JAK2 (0.50) | TYK2JAK2JAK1PDE4DALDH1A1 | |
| SCHEMBL2422229 | 0.87 | JAK2 (0.50) | TYK2JAK2JAK1PDE4DALDH1A1 | |
| SCHEMBL24498001 | 0.87 | TYK2 (0.51) | TYK2JAK2JAK1PDE4DALDH1A1 | |
| SCHEMBL2337440 | 0.86 | TYK2 (0.55) | TYK2JAK2JAK1PDE4DSTAT3 | |
| SCHEMBL26534720 | 0.86 | TYK2 (0.50) | TYK2JAK2JAK1PDE4DKCNH2 | |
| SCHEMBL15713447 | 0.85 | TYK2 (0.49) | TYK2JAK2JAK1PDE4DPDE4B | |
| SCHEMBL17207248 | 0.85 | TYK2 (0.50) | TYK2JAK2JAK1PDE4DKCNH2 | |
| SCHEMBL28662530 | 0.84 | JAK2 (0.47) | TYK2JAK2JAK1PDE4DALDH1A1 | |
| SCHEMBL17207261 | 0.82 | TYK2 (0.69) | TYK2JAK2JAK1PDE4DKCNH2 | |
| SCHEMBL26101076 | 0.82 | TYK2 (0.61) | TYK2JAK2JAK1PDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066078-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES | BRISTOL MYERS SQUIBB PHARMA COMPANY (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9987266-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170209426-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| EP-2922841-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663467-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160280649-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015069310-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2014074660-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280649-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | TYK2, IFNAR1, IFNG | TYK2 1/4885JAK2 22/4885JAK1 16/4885 |
| US-20170209426-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNalpha RESPONSES | IFNAR1, TYK2, IFNG | TYK2 2/4885JAK2 21/4885JAK1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.